PTC Therapeutics (PTCT) Misses Q3 EPS by 22c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to PTC Therapeutics (PTCT) Misses Q3 EPS by 22c

PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

November 2, 2017 4:01 PM EDT

SOUTH PLAINFIELD, N.J., Nov. 2, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2017.

"Our performance this quarter combined with our commercial, financial and R&D advancements should allow us to end 2017 in a strong position," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Our commercial success is driven by our mission of improving the lives of patients with Duchenne."

Third Quarter Financial Highlights:

Translarna net product sales were... More